Imugene Limited announced a change to a key management role. Imugene's Chief Medical Officer (CMO) Dr. Rita Laeufle will be retiring from her role and the Company at the end of January Dr. Laeufle has played an important role in advancing Imugene's clinical efforts and the board. Imugene is in the final negotiation to bring in a high calibre oncologist and clinical developer as a CMO to further strengthen its experienced executive team, the company will update the market on this appointment at a later time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.069 AUD | -4.17% | -8.00% | -37.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.27% | 352M | |
+42.53% | 50.93B | |
-0.47% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.51% | 26.02B | |
-22.09% | 18.9B | |
+7.57% | 13.21B | |
+24.04% | 12.17B | |
+30.19% | 12.16B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Imugene Limited Announces Retirement of Rita Laeufle as Chief Medical Officer and the Board